Paper Details

  1. Home
  2. Paper Details

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis.

Author: AguilarAlejandro Javier, AlberaPaula Alejandra, BerraMartín Lucas, Del PapaMelina Sol, GiradoFernada, MariniMaría Cecilia, PasseriniMaría Silvia

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

This clinical trial compared the efficacy and safety of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops for allergic conjunctivitis. Both medications were effective, but BB-PF was superior in resolving non-ocular symptoms and was safer for the ocular surface.
Paper Details　
Original Abstract of the Article :
PURPOSE: To study the efficacy and toxic effects of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops on the ocular surface of patients with allergic conjunctivitis. PATIENTS AND METHODS: Ninety-seven patients with allergic conjunctivitis diagnosi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658941/

データ提供：米国国立医学図書館（NLM）

Bepotastine Besilate: A New Frontier in Allergic Conjunctivitis Treatment

The relentless itch of allergic conjunctivitis can be a major source of discomfort and annoyance. This study delves into the effectiveness of two eye drops: bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK), in treating allergic conjunctivitis. The researchers conducted a randomized, double-blind, controlled, parallel-group clinical trial to compare the efficacy and safety of these medications.

Bepotastine Besilate: A Potential Solution for Allergic Conjunctivitis

The study demonstrates that BB-PF is a promising treatment option for allergic conjunctivitis. While both BB-PF and OL-BAK showed similar efficacy in alleviating ocular signs and symptoms, BB-PF exhibited a higher probability of reducing ocular itching and was superior in resolving non-ocular symptoms associated with allergic conjunctivitis. Imagine a desert oasis where travelers can find relief from the harsh desert conditions. BB-PF could be that oasis for those battling allergic conjunctivitis, offering a pathway to comfort and relief.

A Safer Option for the Ocular Surface

The study also highlights the importance of considering the potential toxic effects of preservatives in eye drops. BB-PF, being preservative-free, demonstrated a safer profile for the ocular surface compared to OL-BAK. This underscores the importance of choosing medications that are not only effective but also gentle on sensitive tissues. It's like navigating a desert with a careful eye for the terrain – choosing the right path can prevent unnecessary strain and discomfort.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of BB-PF in treating allergic conjunctivitis. Its efficacy in reducing ocular itching and its safety for the ocular surface make it a promising alternative to traditional treatments. It's like discovering a hidden oasis in the vast desert of allergic conjunctivitis treatments, offering a path to relief and a healthier ocular environment.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-01
Further Info :

Pubmed ID

38026598

DOI: Digital Object Identifier

PMC10658941

Related Literature

Article Analysis
・Effects of bepotastine ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.